Toggle navigation
Home
Search
Services
Blog
Contact
About
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter
Idec Pharmaceuticals Corporation, San Diego, CA, United States
Search 10 grants from Peter Brams
Search grants from Idec Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The role of protein O-linked N-Acetylglucosamine in regulating cardiac physiology
Research Core
Angiotensin II Induced Growth of Vascular Smooth Muscle
Sociocultural Influences on African American Longevity
Immunobiology of the Olfactory Mucosa
Recently added grants:
Platelet Reprogramming During Inflammation
Neural Metabolic Stress in mTBI and PTSD
Signaling Pathways and Therapeutic Targeting of Leukemic Cells
The Role of Effort Discounting in the Link between Insomnia and Depression
Preventing Diabetic Foot Ulcers through Manipulating the Skin Microbiota
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036027-02A1
Application #
2072058
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-08-15
Project End
1998-04-30
Budget Start
1996-05-01
Budget End
1997-04-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Idec Pharmaceuticals Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Related projects
NIH 1997
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
NIH 1996
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
Comments
Be the first to comment on Peter Brams's grant